Swiss pharmaceutical company Roche has announced that its experimental dual-acting obesity drug, enicepatide, helped overweight or obese patients living with type 2 diabetes achieve an average body weight reduction of 15.5% while also significantly lowering blood sugar levels in a mid-stage clinical trial.
The results position Roche as a serious contender in the rapidly expanding obesity drug market, where it competes alongside large pharmaceutical companies including AstraZeneca and Amgen, all vying to challenge the current market leaders, Eli Lilly and Novo Nordisk.
How Enicepatide Works
Enicepatide is a once-weekly injection that mimics two hormones — GLP-1 and GIP — to reduce appetite and regulate blood sugar levels. The Roche obesity drug targets both metabolic pathways simultaneously, which is central to its dual-acting mechanism.
Patients who received 24 milligrams of enicepatide — the highest dose tested — demonstrated significant reductions in HbA1c levels at 48 weeks, meeting the two primary endpoints of the study. HbA1c is a widely used clinical measure of blood-glucose levels over a sustained period.
Approximately 62% of patients in the trial achieved HbA1c levels below 5.7%, effectively bringing their blood sugar readings into the non-diabetic range, according to Roche.
Trial Size, Safety, and Tolerability
The mid-stage study enrolled 447 patients. Of those receiving enicepatide, around 2% discontinued treatment due to side effects, compared with none in the placebo group. Roche noted that most gastrointestinal side effects observed — which are common across this class of medications — were mild to moderate in nature.
Earlier Results and Market Context
In a separate mid-stage trial reported in June, enicepatide demonstrated even stronger results among overweight or obese patients without type 2 diabetes, with participants losing an average of 22.7% of their body weight. That earlier data further underscored the potential of the weight loss drug across different patient populations.
Roche is investing in next-generation treatments within a market projected to exceed $100 billion annually within the next decade, reflecting the scale of commercial opportunity in the obesity and metabolic disease space.
Next Steps: Late-Stage Trials Planned for 2027
Roche has confirmed plans to initiate late-stage glycemic-control and cardiovascular outcomes studies in the first half of 2027. These trials will be critical in advancing enicepatide through the regulatory pipeline and determining its broader clinical profile.
The progression of enicepatide into late-stage development reflects Roche’s broader ambition to establish a strong position in the obesity drug segment as global demand for effective, long-term weight management therapies continues to grow.
